Detalles de la búsqueda
1.
Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma.
N Engl J Med
; 390(4): 301-313, 2024 Jan 25.
Artículo
en Inglés
| MEDLINE | ID: mdl-38084760
2.
Elotuzumab plus pomalidomide and dexamethasone in relapsed/refractory multiple myeloma: a multicenter, retrospective, real-world experience with 200 cases outside of controlled clinical trials.
Haematologica
; 109(1): 245-255, 2024 01 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-37439329
3.
A real-life study of daratumumab combinations in newly diagnosed patients with light chain (AL) amyloidosis.
Hematol Oncol
; 42(4): e3289, 2024 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-38824453
4.
Elotuzumab plus pomalidomide and dexamethasone in relapsed/refractory multiple myeloma: Extended follow-up of a multicenter, retrospective real-world experience with 321 cases outside of controlled clinical trials.
Hematol Oncol
; 42(4): e3290, 2024 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-38818978
5.
Lenalidomide-based triplet regimens in first relapsed multiple myeloma patients: real-world evidence from a propensity score matched analysis.
Haematologica
; 108(3): 833-842, 2023 03 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-36200419
6.
Elotuzumab plus lenalidomide and dexamethasone in relapsed/refractory multiple myeloma: Extended 3-year follow-up of a multicenter, retrospective clinical experience with 319 cases outside of controlled clinical trials.
Hematol Oncol
; 40(4): 704-715, 2022 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-35608183
7.
Adjusted comparison between elotuzumab and carfilzomib in combination with lenalidomide and dexamethasone as salvage therapy for multiple myeloma patients.
Eur J Haematol
; 108(3): 178-189, 2022 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-34716957
8.
A risk-stratification model based on the initial concentration of the serum monoclonal protein and MYD88 mutation status identifies a subset of patients with IgM monoclonal gammopathy of undetermined significance at high risk of progression to Waldenström macroglobulinaemia or other lymphoproliferative disorders.
Br J Haematol
; 187(4): 441-446, 2019 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-31276195
9.
The amyloidogenic light chain is a stressor that sensitizes plasma cells to proteasome inhibitor toxicity.
Blood
; 129(15): 2132-2142, 2017 04 13.
Artículo
en Inglés
| MEDLINE | ID: mdl-28130214
10.
Is re-challenge still an option as salvage therapy in multiple myeloma? The case of REal-life BOrtezomib re-Use as secoND treatment for relapsed patients exposed frontline to bortezomib-based therapies (the REBOUND Study).
Ann Hematol
; 98(2): 361-367, 2019 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-30353388
11.
Nonlymphoplasmacytic lymphomas associated with light-chain amyloidosis.
Blood
; 135(4): 293-296, 2020 01 23.
Artículo
en Inglés
| MEDLINE | ID: mdl-31714952
12.
The possible role of burden of therapy on the risk of myeloma extramedullary spread.
Ann Hematol
; 96(1): 73-80, 2017 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-27766391
13.
Elotuzumab, lenalidomide, and dexamethasone as salvage therapy for patients with multiple myeloma: Italian, multicenter, retrospective clinical experience with 300 cases outside of controlled clinical trials.
Haematologica
; 106(1): 291-294, 2021 01 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-32107338
14.
Prevalence and clinical significance of the MYD88 (L265P) somatic mutation in Waldenstrom's macroglobulinemia and related lymphoid neoplasms.
Blood
; 121(13): 2522-8, 2013 Mar 28.
Artículo
en Inglés
| MEDLINE | ID: mdl-23355535
15.
Anti-BCMA CAR-T cell-based therapies and bispecific antibodies in the immunotherapy era: are we ready for this?
Expert Rev Hematol
; : 1-16, 2024 May 21.
Artículo
en Inglés
| MEDLINE | ID: mdl-38770902
16.
A real-world retrospective-prospective analysis of efficacy and safety of combined ixazomib, lenalidomide, and dexamethasone in relapsed/refractory multiple myeloma: The northern Italy experience.
Cancer Med
; 13(7): e7071, 2024 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-38558233
17.
Monoclonal gammopathy of undetermined significance: a new proposal of workup.
Eur J Haematol
; 91(4): 356-60, 2013 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-23859528
18.
Good clinical activity and favorable toxicity profile of once weekly bortezomib, fotemustine, and dexamethasone (B-MuD) for the treatment of relapsed multiple myeloma.
Am J Hematol
; 88(2): 102-6, 2013 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-23224960
19.
Response-adjusted ISS (RaISS) is a simple and reliable prognostic scoring system for predicting progression-free survival in transplanted patients with multiple myeloma.
Am J Hematol
; 87(2): 150-4, 2012 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-22189759
20.
An N-glycosylation hotspot in immunoglobulin κ light chains is associated with AL amyloidosis.
Leukemia
; 36(8): 2076-2085, 2022 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-35610346